Anavex Life Sciences News

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

GlobeNewswireDec 9 07:30 ET

Earnings Week Ahead: ORCL, GME, ADBE, COST, AVGO, M and More

Seeking AlphaDec 8 08:01 ET

Anavex Life Sciences Down Over 13%, On Track for Largest Percent Decrease Since January -- Data Talk

Dow JonesDec 5 15:12 ET

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

GlobeNewswireDec 2 07:30 ET

Buy Recommendation for Anavex Life Sciences: Promising Alzheimer's Treatment and Expanding Clinical Pipeline

TipRanksNov 27 06:25 ET

Anavex Submits Marketing Authorization Application to EU Regulator for Blarcamesine to Treat Alzheimer's; Shares Jump Pre-Bell

MT NewswiresNov 26 09:29 ET

Express News | Anavex Life Sciences Announces Submission of Blarcamesine Maa for Treatment of Alzheimer’s Disease to EMA

ReutersNov 26 07:30 ET

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow JonesNov 25 09:15 ET · Ratings

Anavex Life Sciences Price Target Maintained With a $46.00/Share by D. Boral Capital

Dow JonesNov 25 09:15 ET · Ratings

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

GlobeNewswireNov 25 07:30 ET

Express News | Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase Iib/III Data in a Reference Alzheimer’s Disease Journal

ReutersNov 25 07:30 ET

Calendar of U.S. Earnings Expected in the Week Ahead

Dow JonesNov 22 06:00 ET

Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More

Seeking AlphaNov 18 00:09 ET

Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?

Simply Wall StNov 6 08:08 ET

Express News | HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target

BenzingaNov 4 06:29 ET

Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion

TipRanksNov 4 06:15 ET · Ratings

Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.

BenzingaOct 31 14:58 ET

12 Health Care Stocks Moving In Thursday's Intraday Session

BenzingaOct 31 12:34 ET

JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsOct 31 11:32 ET · Ratings

Anavex Life Sciences Is Maintained at Buy by EF Hutton

Dow JonesOct 31 09:13 ET · Ratings